AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries.
It operates through two segments, Contract Research Services and Research Products.
The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services.
This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples.
The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments.
The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally.
It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program.
The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021.
Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Country | United States |
IPO Date | Nov 25, 1997 |
Industry | Medical - Diagnostics & Research |
Sector | Healthcare |
Employees | 1,955 |
CEO | Robert W. Leasure Jr. |
Contact Details
Address: 2701 Kent Avenue West Lafayette, Indiana United States | |
Website | https://www.inotivco.com |
Stock Details
Ticker Symbol | NOTV |
Exchange | NASDAQ |
Fiscal Year | October - September |
Reporting Currency | USD |
CIK Code | 0000720154 |
CUSIP Number | 45783Q100 |
ISIN Number | US45783Q1004 |
Employer ID | 35-1345024 |
SIC Code | 8731 |
Key Executives
Name | Position |
---|---|
Robert W. Leasure Jr. | President, Chief Executive Officer & Director |
Beth A. Taylor CPA | Senior Vice President of Finance & Chief Financial Officer |
John Gregory Beattie DSA | Chief Operating Officer of DSA |
Andrea Castetter | SVice President of General Counsel, Corporate Secretary & Chief Compliance Officer |
Brennan Freeman | Vice President of Finance, Principal Accounting Officer & Corporate Controller |
Dr. Adrian Hardy Ph.D. | Chief Commercial Officer |
Dr. John E. Sagartz D.V.M., DiplomateACVP, Ph.D. | Chief Strategy Officer & Director |
Dr. Peter T. Kissinger | Founder, Chairman Emeritus & Scientific Advisor |
Jeffrey Arthur Krupp | Chief Human Resources Officer |
Lizanne Muller | Group President of RMS |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 10, 2025 | 424B7 | Filing |
Dec 23, 2024 | 4 | Filing |
Dec 18, 2024 | 8-K | Current Report |
Dec 18, 2024 | 424B5 | Filing |
Dec 17, 2024 | 424B5 | Filing |
Dec 12, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |
Dec 04, 2024 | 10-K | Annual Report |